Study on the Effect of Chemotherapy with Ifosfamide, Dacarbazine, and Epirubicin Hydrochloride Before Surgery for Patients with High-Risk Retroperitoneal Sarcoma

Registered drugNo placebo

Study on the Effect of Chemotherapy with Ifosfamide, Dacarbazine, and Epirubicin Hydrochloride Before Surgery for Patients with High-Risk Retroperitoneal Sarcoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Dacarbazine
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

Sickle cell disease

Recruiting

Study on Tocilizumab for Treating Acute Chest Syndrome in Children and Adults with Sickle Cell Disease

Registered drug

Study on Tocilizumab for Treating Acute Chest Syndrome in Children and Adults with Sickle Cell Disease

Registered drug

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Sodium Chloride
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Early Detection and Treatment of ER Positive HER2 Negative Breast Cancer Using Palbociclib, Fulvestrant, and Drug Combination for Patients with Molecular Relapse

Registered drugNo placebo

Study on Early Detection and Treatment of ER Positive HER2 Negative Breast Cancer Using Palbociclib, Fulvestrant, and Drug Combination for Patients with Molecular Relapse

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:The Royal Marsden NHS Foundation Trust

Contact Research Centre

Non-small cell lung cancer recurrent

Recruiting

Study of Taletrectinib for Patients with Advanced or Metastatic ROS1 Positive Non-Small Cell Lung Cancer

InvestigationalNo placebo

Study of Taletrectinib for Patients with Advanced or Metastatic ROS1 Positive Non-Small Cell Lung Cancer

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Taletrectinib
Sponsor:Nuvation Bio Inc.

Contact Research Centre

Brain stem glioma

Recruiting

Study on ONC201 and Everolimus with Radiotherapy for Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Other Diffuse Midline Gliomas in Children, Adolescents, and Adults

Registered drugNo placebo

Study on ONC201 and Everolimus with Radiotherapy for Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Other Diffuse Midline Gliomas in Children, Adolescents, and Adults

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Dordaviprone
Sponsor:Institut Gustave Roussy

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Saint-Cloud

What the registry says about research in the country

01 Blood Cancer Research

Innovative trials focusing on lymphoma and multiple myeloma treatments, including studies of novel therapies like duvelisib for T-cell lymphoma and odronextamab for follicular lymphoma.

B-Cell Lymphomas
Multiple Myeloma
T-Cell Lymphomas

Several studies are evaluating combination therapies and comparing new treatment approaches against standard care.

02 Breast Cancer Studies

Comprehensive research into various types of breast cancer, with particular focus on hormone receptor-positive and triple-negative variants. Studies include early detection methods and novel therapeutic combinations.

HR+/HER2- Advanced Breast Cancer
Triple-Negative Breast Cancer
Early-Stage Disease

Trials incorporate innovative approaches like ctDNA monitoring and targeted therapies.

03 Advanced Cancer Therapies

Research focusing on targeted therapies for various advanced cancers, including studies of biliary tract cancer and non-small cell lung cancer treatments.

Lung Cancer
Biliary Tract Cancer
Prostate Cancer

Emphasis on immunotherapy combinations and precision medicine approaches.

Back to France All countries